| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$12,259,884 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$12,259,884 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-14 |
4 |
AS |
$232.02 |
$567,057 |
D/D |
(2,444) |
57,438 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-18 |
4 |
AS |
$229.22 |
$995,949 |
D/D |
(4,312) |
49,687 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-25 |
4 |
AS |
$229.41 |
$1,748,990 |
D/D |
(7,572) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-07-19 |
4 |
AS |
$286.72 |
$5,156,730 |
D/D |
(17,865) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-08-08 |
4 |
AS |
$290.32 |
$381,469 |
D/D |
(1,304) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-11-07 |
4 |
AS |
$299.72 |
$394,859 |
D/D |
(1,303) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-11-15 |
4 |
AS |
$308.61 |
$10,493 |
D/D |
(34) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-06 |
4 |
AS |
$300.39 |
$399,022 |
D/D |
(1,304) |
68,645 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-13 |
4 |
AS |
$296.44 |
$1,434,126 |
D/D |
(4,798) |
54,396 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-14 |
4 |
AS |
$295.79 |
$1,911,108 |
D/D |
(6,398) |
47,998 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-21 |
4 |
AS |
$291.01 |
$1,175,676 |
D/D |
(4,002) |
40,246 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-27 |
4 |
AS |
$287.23 |
$1,218,449 |
D/D |
(4,238) |
32,038 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-08-09 |
4 |
AS |
$345.51 |
$21,767 |
D/D |
(63) |
32,038 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-11-15 |
4 |
AS |
$369.92 |
$7,028 |
D/D |
(19) |
32,038 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-12 |
4 |
AS |
$420.24 |
$1,321,655 |
D/D |
(3,145) |
47,588 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-20 |
4 |
AS |
$420.79 |
$1,684,002 |
D/D |
(4,002) |
37,024 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-21 |
4 |
AS |
$421.77 |
$1,266,154 |
D/D |
(3,002) |
34,022 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-26 |
4 |
AS |
$425.70 |
$1,804,542 |
D/D |
(4,239) |
25,813 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Scientific Officer |
• – – |
2024-05-15 |
4 |
AS |
$430.93 |
$23,270 |
D/D |
(54) |
25,813 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-10 |
4 |
D |
$240.95 |
$3,206,563 |
D/D |
(13,308) |
57,002 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-17 |
4 |
D |
$241.50 |
$602,784 |
D/D |
(2,496) |
37,474 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-24 |
4 |
D |
$239.23 |
$577,980 |
D/D |
(2,416) |
31,930 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-10 |
4 |
D |
$214.16 |
$636,912 |
D/D |
(2,974) |
58,381 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-17 |
4 |
D |
$211.75 |
$1,321,320 |
D/D |
(6,240) |
46,858 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-24 |
4 |
D |
$217.57 |
$525,649 |
D/D |
(2,416) |
36,617 |
0 |
- |
|
157 Records found
|
|
Page 4 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
